Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arcoma ABOSTO:ARCOMA -0.25%75 Return-on-Tangible-Equity is 5.55% as of Mar. 2026, which is 31% below its 10-year median of 8.07. GuruFocus rates OSTO:ARCOMA with a GF Score™ of 75/100 and a GF Value™ of kr7.87 (Fairly Valued). The stock has 1 warning sign investors should review. Among 760 Medical Devices & Instruments companies, Arcoma AB ranks better than 58.55% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Arcoma AB's annualized net income for the quarter that ended in Mar. 2026 was kr3.2 Mil. Arcoma AB's average shareholder tangible equity for the quarter that ended in Mar. 2026 was kr58.5 Mil. Therefore, Arcoma AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 5.55%.
The historical rank and industry rank for Arcoma AB's Return-on-Tangible-Equity or its related term are showing as below:
OSTO:ARCOMA'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -67.31 Med: 8.07 Max: 31.89
Current: 7.34
During the past 13 years, Arcoma AB's highest Return-on-Tangible-Equity was 31.89%. The lowest was -67.31%. And the median was 8.07%.
OSTO:ARCOMA's Return-on-Tangible-Equity is ranked better than 58.55% of 760
companies
in the Medical Devices & Instruments industry
Industry Median: 4.03
vs OSTO:ARCOMA: 7.34
Arcoma AB (OSTO:ARCOMA) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Arcoma AB Return-on-Tangible-Equity Related Terms
Arcoma AB Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Arcoma AB's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ARCOMA vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Arcoma AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcoma AB Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Arcoma AB's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Arcoma AB's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 5.55% mean?
Arcoma AB (OSTO:ARCOMA) has a Return-on-Tangible-Equity of 5.55% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Arcoma AB and its competitors. This is 31% below median its historical median of 8.07. According to the industry distribution chart, Arcoma AB ranks #315 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 41.4%.
Is Arcoma AB's Return-on-Tangible-Equity too high?
Arcoma AB's current Return-on-Tangible-Equity of 5.55% is 31% below median its 10-year median of 8.07. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.03. Arcoma AB's value of 5.55% is 37.7% above this industry median. Based on the distribution chart, Arcoma AB ranks #315 out of 760 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Arcoma AB has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arcoma AB's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Arcoma AB ranks #315 out of 760 companies for Return-on-Tangible-Equity. This puts Arcoma AB in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.03. Arcoma AB's value of 5.55% is 37.7% above this benchmark. While the company's 10-year median is 8.07 vs. the industry median of 4.03, Arcoma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.03, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcoma AB's current Return-on-Tangible-Equity of 5.55% is 37.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Arcoma AB and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcoma AB's current Return-on-Tangible-Equity is 5.55%, which is 31% below median its own 10-year median of 8.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcoma AB stock overvalued right now?
Based on GuruFocus' analysis, Arcoma AB (OSTO:ARCOMA) is currently considered Fairly Valued. The stock's GF Value™ is kr7.87, compared to a current price of kr8.04 — trading 2.2% above its estimated fair value. The current Return-on-Tangible-Equity is 5.55%, which is 31% below median its 10-year median of 8.07 and 37.7% above the Medical Devices & Instruments industry median of 4.03. Arcoma AB's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Arcoma AB (OSTO:ARCOMA), the current Return-on-Tangible-Equity is 5.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcoma AB (OSTO:ARCOMA) Overvalued in 2026?
Based on GuruFocus' analysis, Arcoma AB stock appears to be overvalued.
The current stock price of kr8.04 is trading 2.2% above its estimated GF Value™ of kr7.87.
GuruFocus considers Arcoma AB to be Fairly Valued.
Key valuation signals for OSTO:ARCOMA:
Return-on-Tangible-Equity: 5.55% (31% below median its 10-year median of 8.07)
GF Value™: kr7.87 vs. price of kr8.04 (2.2% above fair value)
Industry Position: 37.7% above the Medical Devices & Instruments median (#315 of 760)
No single metric tells the full story. See the OSTO:ARCOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcoma AB provides digital radiography systems in Sweden. It offers products including wireless flat panel detectors, positioning devices, and precision dr systems.
75GF Score
Get the complete analysis for OSTO:ARCOMA
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ARCOMA has been successfully added to your 
